CNS Pharmaceuticals

CNS Pharmaceuticals is a preclinical-stage pharmaceutical company focused on developing anticancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug, Berubicin, represents an innovative discovery for the treatment of glioblastoma multiforme (GBM) and potentially other malignant central nervous system tumors. Berubicin was originally discovered at MD Anderson Cancer Center, one of the largest cancer research institutions in the world. CNS Pharmaceuticals has obtained the global exclusive license for Berubicin from Houston Pharmaceuticals, Inc., the original commercial holder of Berubicin’s intellectual property.